RNS Number : 8040T


29 November 2021

29 November 2021

GENinCode Plc

("GENinCode" or the "Company")

Directorate change

GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces that David Evans, Non-Executive Director, has notified the Board of his intention to stand down from his role with immediate effect.

Bill Rhodes, Non-Executive Chairman of GENinCode Plc said: " We would like to thank David for his invaluable contribution to GENinCode during his tenure. David has worked with members of the GENinCode management team for many years, and he has always provided instrumental strategic advice and counsel from his wealth of experience in the sector. On behalf of the Board, I would like to wish him the very best for the future."

For further information please contact:

 GENinCode Plc                                             www.genincode.com or via Walbrook 
 Matthew Walls, CEO 
 Paul Foulger, CFO 
 Stifel Nicolaus Europe Limited (Nomad                              Tel: +44 (0)20 7710 7600 
  and Joint Broker) 
 Alex Price / Ben Maddison / Richard Short 
   Cenkos Securities Plc (Joint Broker)                             Tel: +44 (0)20 7397 8900 
 Giles Balleny 
 Dale Bellis / Michael Johnson (Sales) 
 Walbrook PR Limited 
                                              Tel: 020 7933 8780 or genincode@walbrookpr.com 
 Anna Dunphy / Paul McManus / Louis Ashe-Jepson 

About GENinCode plc

GENinCode plc is engaged in the risk assessment, prediction and prevention of cardiovascular disease ("CVD"). CVD is the leading cause of death worldwide accounting for approximately 18 million deaths annually. The Company's products and technology have been developed with the aim of predicting the onset of CVD and providing a personalised treatment pathway for patient management. Its products have been the subject of clinical studies on over 75,000 patients to assess and predict the onset of CVD.

The Company was incorporated in September 2018 to acquire the assets, intellectual property and know-how of the Ferrer inCode and Gendiag.exe businesses, which were then part of Grupo Ferrer Internacional S.A., a large Spanish multinational private pharmaceutical and healthcare company. The technology and products acquired included Cardio inCode(R), Lipid inCode(R), Thrombo inCode(R) and Sudd inCode(R). Approximately EUR50 million has been invested in the research and development of these products since 2007. The Company has begun to commercialise these products in Europe and is also targeting the UK and US.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

November 29, 2021 02:00 ET (07:00 GMT)

Genincode (LSE:GENI)
Historical Stock Chart
From Jul 2022 to Aug 2022 Click Here for more Genincode Charts.
Genincode (LSE:GENI)
Historical Stock Chart
From Aug 2021 to Aug 2022 Click Here for more Genincode Charts.